Report from the 20th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28–29 September 2018
Duc Le(University of Saskatchewan), Tooba Asif(University of Saskatchewan), Karen Mulder, Janine M. Davies(Australian Wildlife Conservancy), Bryan Brunet(University of Saskatchewan), Shahid Ahmed(Emory University), M. Ferguson(Saskatchewan Cancer Agency), Richard M. Lee‐Ying(Alberta Health Services), Trevor D. Hamilton(Vancouver General Hospital), Pamela Hebbard(University of Manitoba), Jonathan M. Loree(University of British Columbia), John Paul McGhie(BC Cancer Agency), Christina Kim, Ramzi M. Helewa(University of Manitoba), Howard J. Lim(BC Cancer Agency), Jungeun Park(CancerCare Manitoba), Ralph Wong(CancerCare Manitoba), Vinessa Gordon(CancerCare Manitoba), Nathan Ginther(University of Saskatchewan), Daniel J. Renouf(BC Cancer Agency), A. Zaidi(University of Saskatchewan), C. Döll(University of Alberta)
Cited by 1
Related Papers
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
|Cancers|2023|640
Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018
|JAMA Oncology|2019|568
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|436
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
|European Journal of Cancer|2015|337